Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on April 14, 2020, 12:24:50 pm
-
Ocaliva (obeticholic acid) significantly improved liver fibrosis related to non-alcoholic steatohepatitis (NASH), though it did not lead to NASH resolution, according to a recently published study. The medication is scheduled for a Food and Drug Administration (FDA) review in April 2020.
Zobair Younossi, MD, PhD, of Inova Fairfax Medical Campus in Falls Church, Virginia, and colleagues conducted the Phase III REGENERATE trial to evaluate Ocaliva, being developed by Intercept Pharmaceuticals, as a treatment for NASH. Interim results were published in The Lancet in December and presented at the 2019 International Liver Congress last April
“This study is a pivotal step for the development of drugs to treat NASH and is likely to be the first to receive regulatory approval,” wrote the authors of an editorial accompanying the study.
For more...
https://www.hepmag.com/article/ocaliva-improves-liver-fibrosis-people-nash